AVBP

Arrivent Biopharma Inc

• TipRanks·1d ago

  Analysts Have Conflicting Sentiments on These Healthcare Companies: ArriVent BioPharma, Inc. (AVBP) and Oncolytics Biotech (ONCY)

• TipRanks·5d ago

  JonesTrading Remains a Buy on ArriVent BioPharma, Inc. (AVBP)

• NASDAQ·5d ago

  Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

• Seeking Alpha·03/24 11:02

  ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib

• Dow Jones·03/23 16:20

  ArriVent BioPharma Is Maintained at Buy by B. Riley Securities

• Dow Jones·03/23 16:20

  ArriVent BioPharma Price Target Raised to $45.00/Share From $37.00 by B. Riley Securities

• Benzinga·03/23 16:10

  B. Riley Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45

• TipRanks·03/23 12:51

  ArriVent Biopharma price target raised to $45 from $37 at B. Riley

• Reuters·03/23 07:35

  U.S. RESEARCH ROUNDUP- ArriVent Biopharma, Aveanna Healthcare Holdings, EQT

• Reuters·03/23 03:12

  ARRIVENT BIOPHARMA INC <AVBP.O>: B. RILEY RAISES TARGET PRICE TO $45 FROM $37

• TipRanks·03/17 21:31

  ArriVent Highlights Next-Generation Oncology Data at AACR 2026

• Benzinga·03/17 21:19

  ArriVent BioPharma To Reveal Two Preclinical Posters On The EGFR Inhibitor Firmonertinib And On the Novel Dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 At The 2026 AACR Annual Meeting

• Reuters·03/17 21:00

  ArriVent to present two preclinical posters at the AACR Annual Meeting

• Dow Jones·03/12 11:01

  ArriVent BioPharma Coverage Assumed by BTIG at Buy

• Dow Jones·03/12 11:01

  ArriVent BioPharma Price Target Announced at $42.00/Share by BTIG